BRAIN Biotech : Management Statement - 16 Januar 2023 (nur in englisch verfügbar)

BRAIN Biotech AG

Creating a #BiobasedFuture

Analyst Call 12M, FY 2021/22

Adriaan Moelker, CEO

Michael Schneiders, CFO

Zwingenberg, January 16th, 2023

Since 2021 we have been committed to the UN Global Compact corporate responsibility

initiative and its principles in the areas of human rights, labor, the environment and anti-corruption.

Creating a #BiobasedFuture

© BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com [phone]

1

Safe Harbor Statement

This document may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties, as they relate to future events and are based on current assumptions of the Company, which may not occur at all in the future or may not occur as assumed. They do not represent a guarantee for future results or performance of the Company, and the development of economic and legal conditions may materially differ from the information expressed or implied in the forward-looking statements.

The Company assumes no obligation to update or revise any forward-looking statement contained herein or to adapt them to future events or developments. The information contained in this document has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinion contained herein. The Company or any of its shareholders, affiliates, advisors, employees or representatives shall have no liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its content or otherwise arising in connection with this document.

By accepting this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsibility for forming your own view of the potential future performance of the Company's business.

This presentation speaks as of January 16th, 2023. Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The term "BRAIN", as used in this presentation means Brain Biotech AG and its affiliates, if not otherwise specified.

Creating a #BiobasedFuture

© BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com [phone]

2

Highlights FY 21/22

delivering on strong topline growth and rising profitability

• BRAIN Group: Back to organic growth in both divisions. Breatec adds M&A based growth on top. Ongoing strong cost control, including harvesting group synergies. Significantly improved profitability and reduced operating cash-burn. First ESG report published
• Breatec: successful acquisition and integration. Set to become a future driver of organic growth
• BioScience: BRAIN Zwingenberg fully recovered to pre-pandemic revenue levels. Increasing level of TMS+ business. CRISPR remains a differentiator and USP
• Biocatalysts: strong underlying business growth. Large first 10m3 fermenter volume fully utilized. Second 10m3 fermenter in successful commissioning
• Incubator Pipeline: Salt Taste Enhancer 1.0 successfully launched to market. New partner found for the Urban Mining / Gold from Waste-Streams project. Akribion Genomics activates genome editing in mammalian cells and BEC considered as a patentable technology.
• L.A. Schmitt: disposal of business at favorable terms to a strong new owner. Exit of product related cosmetics activities. BioIndustrial now fully focused on science intensive product businesses

Creating a #BiobasedFuture

© BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com [phone]

3

Lowlights FY 21/22

supply chain restraints limiting even more dynamic growth

• Supply Chain Constraints: and challenges in the logistics chain hindered even more dynamic organic growth especially in the BioIndustrial segment. Most negatively affected were Biosun and L.A. Schmitt
• Incubator Pipeline:
• • Natural Fermented Beverage (I): failed at consumer tests, no market introduction decision by customer  will exit the Incubator-Pipeline
  • Pharvaris:following a Type A Meeting with the U.S. FDA regarding the previously- announced clinical holds on PHA121, Pharvaris has submitted a protocol for a 26-week rodent toxicology study of PHA121, which is under review by the FDA. Positive top-line data from the RAPIDe-1 clinical study were announced in December 2022. The on- demand program of PHA121 is on partial hold in the U.S. and the prophylactic program remains on full clinical hold. Clinical studies of PHA121 outside the U.S. remain active. (Detailed information: https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-provides-regulatory-clinical-and-corporate-updates)
• WeissBioTech: slow turnaround with sales back to slight growth but below budget. Losses reduced but still below break-even additional measures initiated, turnaround in FY '22/'23

Creating a #BiobasedFuture

© BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com [phone]

4

This is BRAIN

BRAIN Biotech AG

Breakthroughs & Services

BioScience

Incubator		Tailor Made Solutions	BioActive Compound
	Libraries

Products

BioIndustrial

Enzymes Microorganisms Bioactives

Breakthrough Discoveries

Nutrition/Health/Environm.

Big Societal Themes

Focused Pipeline

Own&Partner Investment

• €5m-€7mAnnual
  Investment

Discovery	Proprietary Bio-Archive
Characterization	Bioprospecting
Cellular Biology	Discovery
Bioprocess Development	Customized Search
Gene/Protein Engineering	Third-Party Access
Strain Development/Opt.

• €12.1m Annual Revenues* Profitable Cost-plus Contract Research, Milestones, Technology & License Fees

Nutrition, Healthcare, Environment, Cosmetics

Large Scale Fermentation

Formulating/Blending

Production Scale-up

Cell Factories

Fermented Foods / Precise Fermentation

• €37.5m Annual Revenues ~13% adj. EBITDA Margin*

X

Spin-Out, 35.51% stake

*FY '21/'22

• ~2,2 mio sales deconsolidated Net Cash inflow Q1, ~€2 mio

Creating a #BiobasedFuture

© BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com [phone]

5